Table 1.
Demographic and Clinical Characteristics of the Patients and Controls.*
| Characteristic | Patients | Controls | ||
|---|---|---|---|---|
| Haploidentical Mesenchymal Stromal Cells (N = 7) |
STRO-3+ Mesenchymal Progenitor Cells (N = 24) |
MDACC (N = 60)† |
CIBMTR (N = 80) |
|
| Weight — kg | ||||
| Median | 79 | 75 | 75 | 82 |
| Range | 53–95 | 51–118 | 48–122 | 40–170 |
| Age — yr | ||||
| Median | 31 | 39 | 32 | 36 |
| Range | 26–55 | 18–61 | 18–64 | 18–61 |
| Diagnosis — no. (%) | ||||
| AML or MDS | 5 (71) | 16 (67) | 31 (52) | 52 (65) |
| ALL | 1 (14) | 4 (17) | 15 (25) | 20 (25) |
| Non-Hodgkin’s or Hodgkin’s lymphoma | 0 | 3 (12) | 5 (8) | 7 (9) |
| CLL | 1 (14) | 1 (4) | 2 (3) | 1 (1) |
| CML or other MPD | 0 | 0 | 6 (10) | 0 |
| Myeloma | 0 | 0 | 1 (2) | 0 |
| Disease status at time of transplantation — no. (%) | ||||
| Complete remission | 1 (14) | 12 (50) | 26 (43) | 49 (61) |
| First remission | 1 (14) | 2 (8) | 8 (13) | 17 (21) |
| Second or subsequent remission | 0 | 10 (42) | 18 (30) | 32 (40) |
| Active disease | 6 (86) | 12 (50) | 34 (57) | 31 (39) |
| Donor–recipient HLA compatibility — no. (%) | ||||
| 6/6 | 0 | 1 (4) | 4 (7) | 4 (5) |
| 5/6 | 3 (43) | 3 (12) | 13 (22) | 14 (18) |
| 4/6 | 4 (57) | 20 (83) | 43 (72) | 58 (72) |
| 3/6 | 0 | 0 | 0 | 2 (2) |
| Not reported | 0 | 0 | 0 | 2 (2) |
*
ALL denotes acute lymphocytic leukemia, AML acute myeloid leukemia, CIBMTR Center for International Blood and Marrow Transplant Research, CLL chronic lymphocytic leukemia, CML chronic myeloid leukemia, MDS myelodysplastic syndrome, and MPD myeloproliferative disorder.
†
Two controls from the M.D. Anderson Cancer Center (MDACC) were excluded owing to lack of engraftment and chimerism documentation.